SEARCH

SEARCH BY CITATION

References

  • 1
    Vincenti F, Kirkman R, Light S et al, for the Daclizumab Triple Therapy Study Group. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. New Engl J Med 1998: 338: 161–165.
  • 2
    Nashan B, Light S, Hardie IR, Lin A, Johnson JR. Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group. Transplantation 1999; 67: 110115.
  • 3
    Vincenti F, Laskow DA, Neylan JF, Mendez R, Matas AJ. One-year follow up of an open label trial of FK506 for primary kidney transplantation: a report of the US multicenter FK506 Kidney Transplant Group. Transplantation 1996; 61: 15761581.
  • 4
    Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61: 10291037.
  • 5
    Deierhoi MH, Hudson SL, Gaston RS. Clinical experience with a two dose regimen of daclizumab in cadaveric renal transplantation [abstract]. Transplantation 2000; 69: S260.
  • 6
    Van der Werf WJ, Reed AI, Hemming AW. Two doses of daclizumab provides effective induction for simultaneous pancreas and kidney transplantation [Abstract]. Am J Transplant 2001; 1: 430.
  • 7
    Stratta RJ, Alloway RR, Hodge E, Lo A, Pivot Investigators. Two dose daclizumab regimen provides superior outcomes in simultaneous kidney-pancreas transplant recipients: primary endpoint analysis of a multicenter, randomized study (Abstract #17). Am J Transplant 2002; 2: 142.
  • 8
    Ahsan N, Holman MJ, Yang HC. Limited dose monoclonal IL-2R antibody induction in kidney transplantation – a prospective, randomized, controlled clinical trial (Abstract #1313). Am J Transplant 2002; 2: 469.
  • 9
    Garovoy M, Su S, Amend W, Tomlanovich S, Mould D, Litchman M, Light S. A phase I trial of humanized anti-Tac with standard immunosuppression for the prevention of rejection in renal transplant recipients. Transplantation 1997; 63: 3338.
  • 10
    Laskow DA, Vincenti F, Neylan J, Mendez R, Matas A. Phase II FK506 multicenter concentration control study: one-year follow-up. Transplant Proc 1995; 27: 809811.
  • 11
    The Mycophenolate Mofetil Renal Refractory Rejection Study Group. Mycophenolate mofetil for the treatment of refractory, acute cellular renal transplant rejection. Transplantation 1996; 61: 722729.
  • 12
    Kahan BD for the Rapamune US Study Group. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomized multicenter study. Lancet 2000; 356: 194202.
  • 13
    Vincenti F, Garrod K, Herrera R, Lantz M. Importance of daclizumab concentrations in immunosuppression effectiveness: in vitro and in vivo analysis. Transplantation 2002; [abstract 3295]74: 4.